Multiple Myeloma

Business

IDEAYA Biosciences: Market Jitters or Justified Correction? Analyzing the Valuation Divide

IDEAYA Biosciences shares have retreated from recent highs, sparking debate among investors. While a discounted cash flow model suggests deep undervaluation, price-to-sales metrics paint a contrasting picture of a premium stock. We examine the numbers behind the volatility and what it signals for the precision oncology company's future.

Feb 2, 2026

Business

QuidelOrtho's Valuation Under Scrutiny Amid Persistent Revenue Declines and Cash Flow Concerns

Fresh financial data from QuidelOrtho reveals ongoing challenges, including constant currency revenue declines and pressured cash flow, forcing investors to weigh the stock's risk-reward profile as its momentum appears to fade.

Feb 2, 2026

Business

Navigating the EV Slowdown: Why Rivian and BYD Could Be Long-Term Winners

Despite near-term headwinds in the electric vehicle sector, Rivian and BYD are positioning themselves for the next growth cycle through strategic pivots and vertical integration.

Feb 2, 2026

Business

Meta's AI Ambitions and Soaring Stock: Is There Still Room to Run?

Meta Platforms' stock has surged nearly 300% over three years, fueled by aggressive AI investments and cost discipline. As shares hover near record highs, investors are asking: does the current price still offer value, or has the rally priced in all future growth? A deep dive into valuation metrics suggests the story may be more nuanced than headlines imply.

Feb 2, 2026

Business

A Ponzi in the Parts Aisle: How First Brands' Founders Allegedly Engineered a $9 Billion Collapse

Federal prosecutors have charged the founders of the once-dominant auto parts supplier First Brands Group with orchestrating a massive, years-long fraud, alleging a scheme that misled lenders and ultimately led to the company's catastrophic bankruptcy, sending shockwaves through the industry.

Feb 2, 2026

Business

Beyond the GLP-1 Hype: Is Novo Nordisk's Diversified Pipeline Its Hidden Strength?

While Wall Street chases the latest weight-loss drug headlines, Novo Nordisk's recent launch of an oral GLP-1 therapy and its entrenched insulin business present a compelling value proposition for long-term investors.

Feb 2, 2026

Business

IBM's Quantum Ambition: How a Century-Old Titan Is Outpacing Startups in the Race for Supremacy

While quantum computing startups capture headlines, IBM's decades-long investment and recent Nighthawk processor breakthrough are drawing serious capital from institutional investors, signaling enduring dominance in the enterprise quantum race.

Feb 2, 2026

Sanofi Halts mRNA Flu Vaccine Trial Amid Surging U.S. Influenza Season

French pharmaceutical giant Sanofi has discontinued development of its experimental mRNA flu vaccine, citing a strategic reprioritization. The decision comes as influenza activity remains high across much of the United States, with significant hospitalizations and deaths reported this season.

Feb 2, 2026

Georgia Authorities Bust Alleged $1 Million Title Fraud Ring, Exposing Risks for Unlicensed Drivers and Legitimate Buyers

A multi-year investigation in North Georgia has led to the indictment of nine individuals accused of running a sophisticated scheme that falsified vehicle paperwork, enabling unlicensed drivers to illegally purchase and register cars while netting over $1 million.

Feb 2, 2026

Business

Affluent Foundation's Pivot to Finance: A Bold Bet or a Valuation Bubble?

Hong Kong-listed construction firm Affluent Foundation Holdings (SEHK:1757) has unveiled plans to enter the regulated financial services sector, sending its shares on a meteoric rise. As the stock trades at a significant premium, analysts question whether the market is pricing in future success or overlooking execution risks.

Feb 2, 2026

Business

Musk's Empire in Motion: Tesla-SpaceX Merger Talks Signal Pivot to Robotics and AI

Speculation mounts over a potential merger between Tesla and SpaceX, part of a broader strategic realignment under Elon Musk that could see Tesla shift focus from electric vehicles to humanoid robots and autonomous taxis, with xAI potentially in the mix.

Feb 2, 2026

Business

AI Infrastructure Spending Set to Soar Past $500 Billion, Spotlighting Data Center Giant Equinix

As hyperscalers double down on AI, data center REITs like Equinix emerge as a stable, dividend-paying avenue for investors seeking exposure to the infrastructure backbone of the boom.

Feb 2, 2026

Business

Kratos Defense Stock Slump Continues: Valuation Concerns Eclipse Strong Drone Business

Despite its leadership in high-demand defense sectors like drones and hypersonics, Kratos Defense & Security's shares face sustained pressure as investors question its sky-high valuation and cash flow.

Feb 2, 2026

Business

From Paycheck to Portfolio: The Financial and Emotional Leap to Full-Time Real Estate Investing

A wave of experienced investors on Reddit are sharing the pivotal financial and psychological benchmarks that convinced them to leave their W2 jobs behind. The consensus? It's less about net worth and more about sustainable cash flow, strategic planning, and navigating hidden hurdles like financing and healthcare.

Feb 2, 2026

Business

Outdoor Retail Icon Eddie Bauer Nears Chapter 11 Filing, Signaling End for Physical Stores

The century-old outdoor apparel brand, famed for pioneering the quilted down jacket, is preparing to close its North American retail footprint while its licensing and e-commerce operations continue under new management.

Feb 2, 2026

Business

Nvidia's H200 Chips Clear Chinese Hurdle: Tech Giants Secure First Shipments, Boosting Growth Outlook

Chinese regulators have greenlit the first wave of Nvidia's advanced H200 AI chip orders for major firms including Alibaba and ByteDance, marking a potential turning point for the chipmaker's access to a critical market and fueling optimism for its stock trajectory.

Feb 2, 2026

Business

Revvity Beats 2025 Forecasts on Diagnostics Strength, Offers Cautious 2026 Outlook

Life sciences and diagnostics firm Revvity (RVTY) closed 2025 with results surpassing internal targets, driven by robust diagnostics performance. While management provided initial 2026 guidance, it remains conservative, banking on market stabilization rather than a broad recovery.

Feb 2, 2026

Business

Three Hidden Gems: Undervalued Stocks Poised for a Rebound in February 2026

Amidst a resilient market backdrop, we spotlight three U.S. stocks trading significantly below their estimated intrinsic value, offering potential for investors willing to navigate current volatility.

Feb 2, 2026

Business

Boise Cascade's Shareholder Returns Outpace Earnings, Highlighting Market Sentiment Shift

While Boise Cascade's five-year total shareholder return of 110% has significantly outperformed its modest earnings growth, the building materials firm's recent stock slump raises questions about its valuation and future trajectory in a volatile market.

Feb 2, 2026

Business

IDEXX Laboratories Posts Strong Q4 Growth, Unveils Ambitious 2026 Outlook on Diagnostic Innovation

IDEXX Laboratories (IDXX) reported robust double-digit growth for Q4 2025, driven by record placements of its premium diagnostic instruments and expanding test utilization. While acknowledging persistent softness in U.S. veterinary visit volumes, the company outlined a confident initial 2026 forecast, banking on its innovation pipeline and the transformative impact of its inVue Dx system.

Feb 2, 2026